Dose selection for an adjuvanted respiratory syncytial virus F protein vaccine for older adults based on humoral and cellular immune responses

Clinical and Vaccine Immunology

Volumn 24, Issue 9, 2017, Pages

  Falloon, Judith ^a   Talbot, H Keipp ^b   Curtis, Craig ^c   Ervin, John ^d   Krieger, Diane ^e   Dubovsky, Filip ^a   Takas, Therese ^a   Yu, Jing ^a   Yu, Li ^a   Lambert, Stacie L ^a   Villafana, Tonya ^a   Esser, Mark T ^a  

^a MEDIMMUNE   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c Central Florida Pain Centers   (United States)

^d Center for Pharmaceutical Research   (United States)

^e MIAMI RESEARCH ASSOCIATES   (United States)

Author keywords

Adjuvant; Adult; Cell mediated immunity; Respiratory syncytial virus; TLR 4 agonist; Vaccine

Indexed keywords

GAMMA INTERFERON; GLUCOPYRANOSYL LIPID A; HYBRID PROTEIN; IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT; INACTIVATED VACCINE; INFLUENZA VACCINE; NEUTRALIZING ANTIBODY; PLACEBO; RESPIRATORY SYNCYTIAL VIRUS VACCINE; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; CELLULAR IMMUNITY; COMBINATION DRUG THERAPY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG SAFETY; DRUG TOLERABILITY; EMULSION; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HEMAGGLUTINATION INHIBITION; HUMAN; HUMORAL IMMUNITY; INFECTION PREVENTION; INJECTION SITE DISCOMFORT; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE SWELLING; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY SYNCYTIAL VIRUS INFECTION; VACCINATION; VACCINE IMMUNOGENICITY; VIRUS IMMUNITY; VIRUS STRAIN;

EID: 85028954258     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00157-17     Document Type: Article

References (34)

1. Collins PL, Melero JA. 2011. Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years. Virus Res 162:80–99. https://doi.org/10.1016/j.virusres.2011.09.020.
2. Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE. 2005. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med 352:1749 –1759. https://doi.org/10.1056/NEJMoa043951.
3. Walsh EE, Peterson DR, Falsey AR. 2007. Is clinical recognition of respiratory syncytial virus infection in hospitalized elderly and high-risk adults possible? J Infect Dis 195:1046 –1051. https://doi.org/10.1086/511986.
4. Talbot HK, Falsey AR. 2010. The diagnosis of viral respiratory disease in older adults. Clin Infect Dis 50:747–751. https://doi.org/10.1086/650486.
5. Falsey AR, McElhaney JE, Beran J, van Essen GA, Duval X, Esen M, Galtier F, Gervais P, Hwang SJ, Kremsner P, Launay O, Leroux-Roels G, McNeil SA, Nowakowski A, Richardus JH, Ruiz-Palacios G, St Rose S, Devaster JM, Oostvogels L, Durviaux S, Taylor S. 2014. Respiratory syncytial virus and other respiratory viral infections in older adults with moderate to severe influenza-like illness. J Infect Dis 209:1873–1881. https://doi.org/10.1093/ infdis/jit839.
6. Fleming DM, Taylor RJ, Lustig RL, Schuck-Paim C, Haguinet F, Webb DJ, Logie J, Matias G, Taylor S. 2015. Modelling estimates of the burden of respiratory syncytial virus infection in adults and the elderly in the United Kingdom. BMC Infect Dis 15:443. https://doi.org/10.1186/s12879-015-1218-z.
7. Widmer K, Zhu Y, Williams JV, Griffin MR, Edwards KM, Talbot HK. 2012. Rates of hospitalizations for respiratory syncytial virus, human meta-pneumovirus, and influenza virus in older adults. J Infect Dis 206:56–62. https://doi.org/10.1093/infdis/jis309.
8. Malloy AM, Falsey AR, Ruckwardt TJ. 2013. Consequences of immature and senescent immune responses for infection with respiratory syncytial virus. Curr Top Microbiol Immunol 372:211–231. https://doi.org/10.1007/978-3-642-38919-1_11.
9. Schanzer DL, Langley JM, Tam TW. 2008. Role of influenza and other respiratory viruses in admissions of adults to Canadian hospitals. Influenza Other Respir Viruses 2:1–8. https://doi.org/10.1111/j.1750-2659.2008.00035.x.
10. Cherukuri A, Patton K, Gasser RA, Jr, Zuo F, Woo J, Esser MT, Tang RS. 2013. Adults 65 years old and older have reduced numbers of functional memory T cells to respiratory syncytial virus fusion protein. Clin Vaccine Immunol 20:239–247. https://doi.org/10.1128/CVI.00580-12.
11. Walsh EE, Peterson DR, Falsey AR. 2004. Risk factors for severe respiratory syncytial virus infection in elderly persons. J Infect Dis 189:233–238. https://doi.org/10.1086/380907.
12. Bagga B, Cehelsky JE, Vaishnaw A, Wilkinson T, Meyers R, Harrison LM, Roddam PL, Walsh EE, DeVincenzo JP. 2015. Effect of preexisting serum and mucosal antibody on experimental respiratory syncytial virus (RSV) challenge and infection of adults. J Infect Dis 212:1719–1725. https://doi.org/10.1093/infdis/jiv281.
13. Falsey AR, Singh HK, Walsh EE. 2006. Serum antibody decay in adults following natural respiratory syncytial virus infection. J Med Virol 78: 1493–1497. https://doi.org/10.1002/jmv.20724.
14. Hall CB, Walsh EE, Long CE, Schnabel KC. 1991. Immunity to and frequency of reinfection with respiratory syncytial virus. J Infect Dis 163: 693–698. https://doi.org/10.1093/infdis/163.4.693.
15. Coler RN, Bertholet S, Moutaftsi M, Guderian JA, Windish HP, Baldwin SL, Laughlin EM, Duthie MS, Fox CB, Carter D, Friede M, Vedvick TS, Reed SG. 2011. Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant. PLoS One 6:e16333. https://doi.org/10.1371/journal.pone.0016333.
16. Lambert SL, Aslam S, Stillman E, MacPhail M, Nelson C, Ro B, Sweetwood R, Lei YM, Woo JC, Tang RS. 2015. A novel respiratory syncytial virus (RSV) F subunit vaccine adjuvanted with GLA-SE elicits robust protective TH1-type humoral and cellular immunity in rodent models. PLoS One 10:e0119509. https://doi.org/10.1371/journal.pone.0119509.
17. Lambert SL, Yang CF, Liu Z, Sweetwood R, Zhao J, Cheng L, Jin H, Woo J. 2012. Molecular and cellular response profiles induced by the TLR4 agonist-based adjuvant glucopyranosyl lipid A. PLoS One 7:e51618. https://doi.org/10.1371/journal.pone.0051618.
18. Patton K, Aslam S, Shambaugh C, Lin R, Heeke D, Frantz C, Zuo F, Esser MT, Paliard X, Lambert SL. 2015. Enhanced immunogenicity of a respiratory syncytial virus (RSV) F subunit vaccine formulated with the adjuvant GLA-SE in cynomolgus macaques. Vaccine 33:4472–4478. https://doi.org/10.1016/j.vaccine.2015.07.025.
19. Anderson LJ. 2013. Respiratory syncytial virus vaccine development. Semin Immunol 25:160–171. https://doi.org/10.1016/j.smim.2013.04.011.
20. McLellan JS, Ray WC, Peeples ME. 2013. Structure and function of respiratory syncytial virus surface glycoproteins. Curr Top Microbiol Immunol 372:83–104. https://doi.org/10.1007/978-3-642-38919-1_4.
21. Falloon J, Ji F, Curtis C, Bart S, Sheldon E, Krieger D, Dubovsky F, Lambert S, Takas T, Villafana T, Esser MT. 2016. A phase 1a, first-in-human, randomized study of a respiratory syncytial virus F protein vaccine with and without a Toll-like receptor-4 agonist and stable emulsion adjuvant. Vaccine 34: 2847–2854. https://doi.org/10.1016/j.vaccine.2016.04.002.
22. Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez-Domingo J, Hwang SJ, Levin MJ, McElhaney JE, Poder A, Puig-Barbera J, Vesikari T, Watanabe D, Weckx L, Zahaf T, Heineman TC, ZOE-50 Study Group. 2015. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med 372:2087–2096. https://doi.org/10.1056/NEJMoa1501184.
23. Bloom-Feshbach K, Alonso WJ, Charu V, Tamerius J, Simonsen L, Miller MA, Viboud C. 2013. Latitudinal variations in seasonal activity of influenza and respiratory syncytial virus (RSV): a global comparative review. PLoS One 8:e54445. https://doi.org/10.1371/journal.pone.0054445.
24. DiazGranados CA, Dunning AJ, Kimmel M, Kirby D, Treanor J, Collins A, Pollak R, Christoff J, Earl J, Landolfi V, Martin E, Gurunathan S, Nathan R, Greenberg DP, Tornieporth NG, Decker MD, Talbot HK. 2014. Efficacy of high-dose versus standard-dose influenza vaccine in older adults. N Engl J Med 371:635–645. https://doi.org/10.1056/NEJMoa1315727.
25. Falsey AR, Walsh EE. 1998. Relationship of serum antibody to risk of respiratory syncytial virus infection in elderly adults. J Infect Dis 177: 463–466. https://doi.org/10.1086/517376.
26. Lee FE, Walsh EE, Falsey AR, Betts RF, Treanor JJ. 2004. Experimental infection of humans with A2 respiratory syncytial virus. Antiviral Res 63:191–196. https://doi.org/10.1016/j.antiviral.2004.04.005.
27. Luchsinger V, Piedra PA, Ruiz M, Zunino E, Martinez MA, Machado C, Fasce R, Ulloa MT, Fink MC, Lara P, Avendano LF. 2012. Role of neutralizing antibodies in adults with community-acquired pneumonia by respiratory syncytial virus. Clin Infect Dis 54:905–912. https://doi.org/10.1093/cid/cir955.
28. Piedra PA, Jewell AM, Cron SG, Atmar RL, Glezen WP. 2003. Correlates of immunity to respiratory syncytial virus (RSV) associated-hospitalization: establishment of minimum protective threshold levels of serum neutralizing antibodies. Vaccine 21:3479–3482. https://doi.org/10.1016/S0264-410X(03)00355-4.
29. The Impact-RSV Study Group. 1998. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 102: 531–537.
30. U.S. Centers for Disease Control and Prevention. Vaccine administration: recommendations and guidelines. U.S. Centers for Disease Control and Prevention, Atlanta, GA. http://www.cdc.gov/vaccines/recs/vac-admin/default.htm. Accessed 19 October 2015.
31. U.S. Food and Drug Administration. Guidance for industry: toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials. Vaccine administration: recommendations and guidelines. U.S. Food and Drug Administration, Rockville, MD. http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/ Guidances/Vaccines/ucm074775.htm#TOXICITYGRADINGSCALETABLES. Accessed 19 October 2015.
32. Maifeld SV, Ro B, Mok H, Chu M, Yu L, Yamagata R, Leonardson T, Chio V, Parhy B, Park S, Carlson M, Machhi S, Ulbrandt N, Falsey AR, Walsh EE, Wang CK, Esser MT, Zuo F. 2016. Development of electrochemilumines-cent serology assays to measure the humoral response to antigens of respiratory syncytial virus. PLoS One 11:e0153019. https://doi.org/10.1371/journal.pone.0153019.
33. Patton K, Aslam S, Lin J, Yu L, Lambert S, Dawes G, Esser MT, Woo J, Janetzki S, Cherukuri A. 2014. Enzyme-linked immunospot assay for detection of human respiratory syncytial virus F protein-specific gamma interferon-producing T cells. Clin Vaccine Immunol 21:628–635. https://doi.org/10.1128/CVI.00736-13.
34. Falsey AR, Walsh EE, Capellan J, Gravenstein S, Zambon M, Yau E, Gorse GJ, Edelman R, Hayden FG, McElhaney JE, Neuzil KM, Nichol KL, Simoes EA, Wright PF, Sales VM. 2008. Comparison of the safety and immunogenicity of 2 respiratory syncytial virus (RSV) vaccines—nonadjuvanted vaccine or vaccine adjuvanted with alum—given concomitantly with influenza vaccine to high-risk elderly individuals. J Infect Dis 198: 1317–1326. https://doi.org/10.1086/592168.